Y-Biologics is a company specialized in the research and development of novel antibody drugs, striving to become a global leader in the field of antibody therapeutics by concentrating on the discovery of excellent antibodies and establishment of innovative platform technologies.
Y-Biologics is a company specialized in the research and development of novel antibody drugs, striving to become a global leader in the field of antibody therapeutics by concentrating on the discovery of excellent antibodies and establishment of innovative platform technologies.
Y-Biologics is a company specialized in the research and development of novel antibody drugs, striving to become a global leader in the field of antibody therapeutics by concentrating on the discovery of excellent antibodies and establishment of innovative platform technologies.
WHAT WE DOY BIOLOGICS
YBL-006
Korea’s First PD-1 Antibody for Immunotherapy
Our anti-PD-1 antibody binds
to programmed cell death protein-1 (PD-1), an immune checkpoint regulator of T cell activity, to prevent immune evasion and promote the killing of cancer cells.
YBL-013
Application of our Proprietary Bispecific T cell Engager Platform, ALiCE
Applying our proprietary ALiCE technology, we have developed YBL-013 as a successful pipeline that has been licensed out to our overseas partner, 3DMed.
Binding both PD-L1-positive cancer cells and T cells, it recruits T cells to the tumor and induces T cell activation
to eliminate cancer cells.
ALiCE
Proprietary Platform Technology Recognized for its Innovativeness and Originality with a Globally Registered Patent
Designed in a Y-shaped 2-by-1 format similar to the structure of human antibodies, our ALiCE molecules are capable of binding both a designated cancer target and CD3 on T-cells. Binding to CD3 stimulated T-cell activation, enabling T-cells to directly kill cancer cells bound to the bispecific antibodies, and exhibiting higher efficacy in comparison to conventional immune checkpoint inhibitors.
Ymax®-ABL
The Foundation for Y-Biologics’ Pipelines and Open Innovation
Our internally developed and proprietary fully human single-chain variable fragment (scFv) phage display library provides the starting point for each of our novel antibody drug
R&D projects.
FACT SHEETDATA
Company Size
A continuously growing company with 57 executives and employees
Technology Transfers
Antibody R&D Technology Transfers
Open Innovation
Joint Research &Development Projects
Patent Applications
106 Patent Applications Submitted
Patent registration
43 Registered Patents
(As of February 2023)
newsNEWS
partnershipPARTNER
